title: [The changes of the activity of NO-synthases and oxidative processes under conditions of 5-HT receptors activation in the stomach and large intestine in streptozocin-induced diabetes mellitus].
abstract: We investigated the activity of NO-synthases, lipoperoxidation processes, antioxidant defense enzymes in the muscular layers of stomach and large intestine. The L-arginine concentration in blood plasma was also monitored under conditions of 2-weeks activation of 5-HT4 receptors by mosaprid in streptozocin-induced diabetes mellitus. We showed that the onset of diabetes mellitus is accompanied by a 2.4-2.8-fold increase in the activity of inducible NO-synthase and a 23-40% increase in the SOD activity. The nitric oxide content and TBA products in the muscular layers of stomach and large intestine were increased, whereas the motor-evacuational function of the stomach and large intestine decreased. Activation of 5-HT4 receptors by mosaprid under conditions of diabetes mellitus decreased the activity of inducible NO-synthase, the lipoperoxidation processes, nitrite anion content and TBA products in muscular layers of stomach and large intestine by 23%. At the same time, we observed an increase in the motor-evacuational function of stomach and large intestine without affecting the blood sugar level.
authors.forename: O Ia
authors.initials: OIa
authors.lastname: Skliarov
authors.forename: O I
authors.initials: OI
authors.lastname: Detsyk
mesh_terms: D000818:Animals; D001549:Benzamides / Q000008:administration & dosage*; D001786:Blood Glucose / Q000032:analysis; D002374:Catalase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007420:Intestine, Large / Q000187:drug effects* / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D009025:Morpholines / Q000008:administration & dosage*; D009130:Muscle, Smooth / Q000187:drug effects* / Q000378:metabolism; D052248:Nitric Oxide Synthase Type I / Q000037:antagonists & inhibitors / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000378:metabolism; D009573:Nitrites / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D044422:Receptors, Serotonin, 5-HT4 / Q000378:metabolism; D058828:Serotonin 5-HT4 Receptor Agonists / Q000008:administration & dosage*; D013270:Stomach / Q000187:drug effects*; D013311:Streptozocin; D013482:Superoxide Dismutase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances
chemical_list: D001549:Benzamides; D001786:Blood Glucose; D009025:Morpholines; D009573:Nitrites; D058828:Serotonin 5-HT4 Receptor Agonists; D017392:Thiobarbituric Acid Reactive Substances; D044422:Receptors, Serotonin, 5-HT4; D013311:Streptozocin; D002374:Catalase; D052248:Nitric Oxide Synthase Type I; D052247:Nitric Oxide Synthase Type II; C496322:Nos1 protein, rat; C496318:Nos2 protein, rat; D013482:Superoxide Dismutase; C062720:mosapride